Site Editor

Leo I. Gordon, MD, FACP


EHA 2022: Fixed Duration of Bispecific Antibody Glofitamab in Resistant DLBCL

By: Joshua D. Madera, MS
Posted: Tuesday, June 14, 2022

For patients with highly refractory and/or heavily pretreated diffuse large B-cell lymphoma (DLBCL), treatment with the novel T-cell–engaging bispecific antibody glofitamab may improve overall survival, according to a study presented at the European Hematology Association (EHA) 2022 Hybrid Congress (Abstract S220). Fixed-duration treatment with this novel therapy led to “durable” complete remissions in this patient population along with a “favorable” safety profile, explained Michael Dickinson, MBBS, of the University of Melbourne, Australia, and colleagues.

A total of 107 patients with DLBCL who had received at least two prior therapies were recruited for the study. Prior therapies included an anthracycline and anti-CD20 antibody. All patients were administered one dose of intravenous (IV) obinutuzumab 7 days before the first dose of glofitamab. Patients were given 12 cycles of a 21-day treatment regimen, which included a step-up dose of IV glofitamab on days 1 and 8 of the first cycle and a target dose of 30 mg on day 1 of cycles 2 through 12.

The study findings revealed a 50% and 35.2% overall response and complete response rate at a median follow-up of 9 months, respectively. In addition, a projected 12-month overall survival rate was 48%, and 92% of the complete responders survived. Furthermore, 68% of patients experienced symptoms of cytokine-release syndrome, particularly with initial doses.

In terms of safety, symptoms reported were primarily grade 1 (51%) or 2 (12%). Moreover, 3% of patients experienced glofitamab-related adverse events severe enough to require discontinuation of treatment.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.